Rani Therapeutics to Participate in the Evercore Healthcare Conference
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) announced that its management team will participate in the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 8:45 am ET in Coral Gables, FL.
Presenters include CEO Talat Imran and CFO Svai Sanford in a fireside chat and 1x1 meetings. Investors can watch a live webcast via the company Investor Relations website and access a replay after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – RANI
In the Nov 25 session, RANI declined 3.01%, reflecting a moderate negative market reaction. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company’s management team will participate in the upcoming Evercore Healthcare Conference. Details below:
8th Annual Evercore Healthcare Conference
Date: Wednesday, December 3, 2025 at 8:45 am E.T.
Location: Coral Gables, FL
Presenter: Chief Executive Officer, Talat Imran, and Chief Financial Officer, Svai Sanford
Format: Fireside Chat and 1x1 Meetings
Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
